Andreas Clemens | |
|---|---|
 | |
| Born | May 5, 1966 Hildesheim, Low German, Germany |
| Nationality | German |
| Education | University of Göttingen Kiel University University Hospital Heidelberg University of Mainz University of Freiburg |
| Occupation(s) | Medical Director and Head New Medical Brand Incubator & Rare Disease of Novartis |
| Medical career | |
| Profession | Physician |
| Institutions | Novartis |
Andreas Clemens (born May 5, 1966 in Hildesheim) is a German physician.[1] He is an internist, endocrinologist and diabetologist. His main interest is the investigation and development of drugs in the field of cardiology, endocrinology, ophthalmology and very rare diseases.
Life and work
As part of his scientific activities, he has published more than 130 peer-reviewed articles.[2] He has an H-index of 42.[3] He is a member of the European Association for Vision and Eye Research Foundation.[4] He is also an associate editor (editor) at Contemporary Clinical Trials.[5] Furthermore, he is actively involved in teaching at the Albert Ludwigs University of Freiburg, Germany.[6]
References
- ↑ Dabigatranetexilat, ein neuer oraler direkter Thrombininhibitor: Klinische Entwicklung. 2014.
- ↑ "Andreas Clemens - Global Head Medical Affairs Strategy AID & IRD". ResearchGate. Retrieved 3 April 2023.
- ↑ "Andreas Clemens, MD, PhD".
- ↑ "EVER ƒ Members - General Assembly".
- ↑ "Editorial Board - Contemporary Clinical Trials - Journal - Elsevier".
- ↑ "Vorlesungsverzeichnis anzeigen - Campus Management - HISinOne".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.